CW February 2003
Volume 12Issue Number 2 February 2003 ISSN 10593802 Adding Carboplatin to Trastuzumab and Paclitaxel in HER2 + Advanced Breast CancerThe trastuzumab (Herceptin)/paclitaxel (TAXOL) combination has demonstrated superiority to paclitaxel alone in HER2 positive advanced breast cancer patients in past clinical trials. A new trial looking at the addition of a third drug, carboplatin (Paraplatin), showed both improved response rates (RR) and time to progression (TTP).
Go to Previous Page Go to Next Page Source & Additional Reading N. J. Robert, 25th Annual San Antonio Breast Cancer Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
